Melanoma-associated antigen C1
Melanoma-associated antigen C1 (959-968) is a synthetic peptide fragment derived from the C-terminal region of the MAGE-C1 protein, a member of the melanoma-associated antigen family. As a well-characterized epitope, this peptide is recognized for its immunogenic properties and its relevance in tumor immunology research, particularly in the context of melanoma and other malignancies expressing MAGE-C1. The sequence represents a defined region of the antigen that is frequently studied for its capacity to be presented by major histocompatibility complex (MHC) molecules and to elicit specific T cell responses. Its use is pivotal in studies aiming to understand antigen processing, immune recognition, and the molecular mechanisms underlying tumor immune surveillance.
Epitope mapping: The peptide is widely utilized in epitope mapping assays to identify and characterize T cell epitopes within the MAGE-C1 protein. By serving as a defined antigenic sequence, it enables researchers to delineate the precise regions of MAGE-C1 that are recognized by cytotoxic T lymphocytes (CTLs). This information is crucial for unraveling the specificity of anti-tumor immune responses and for the rational design of immunotherapeutic strategies targeting melanoma and other cancers expressing MAGE-C1.
Immunogenicity testing: In vitro immunogenicity assays frequently employ this peptide to evaluate the ability of antigen-presenting cells to process and present MAGE-C1-derived epitopes to T cells. By using defined peptide fragments, investigators can assess the activation, proliferation, and cytokine production of T cells specific to MAGE-C1. Such studies provide valuable insights into the immunological landscape of tumor antigens and inform the selection of candidate epitopes for further development in cancer immunology research.
Peptide-based vaccine research: The defined sequence of this peptide makes it a valuable tool in the preclinical development of peptide-based cancer vaccines. Researchers utilize it to investigate the induction of antigen-specific immune responses, both in vitro and in relevant animal models. These studies contribute to the optimization of vaccine formulations, adjuvant selection, and delivery systems aimed at enhancing the immunogenicity and efficacy of MAGE-C1-targeted vaccines.
T cell functional assays: The peptide serves as a standard reagent in functional assays designed to measure T cell reactivity against MAGE-C1. By stimulating peripheral blood mononuclear cells (PBMCs) or isolated T cell populations with the peptide, researchers can quantify antigen-specific responses using techniques such as ELISPOT, intracellular cytokine staining, or flow cytometry. These assays are instrumental in monitoring immune responses in experimental settings and in the validation of novel immunotherapeutic approaches.
MHC binding studies: The well-defined nature of the peptide sequence enables its application in studies examining peptide-MHC binding affinity and stability. Such investigations are essential for understanding the molecular interactions governing antigen presentation and for predicting the immunodominance of specific epitopes. Data generated from these studies support the rational design of immunotherapies and facilitate the identification of optimal peptide candidates for further translational research.
Collectively, the Melanoma-associated antigen C1 (959-968) peptide is an indispensable reagent in tumor immunology and peptide-based research. Its applications span fundamental studies of immune recognition, translational research in cancer vaccine development, and advanced immunomonitoring techniques, making it a critical tool for advancing the understanding and targeting of tumor-associated antigens in the context of melanoma and related malignancies.
1. The spatiotemporal control of signalling and trafficking of the GLP-1R
2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
3. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More